GlassScriptPhysician profile
Angela Gann
NPI 1841683695
$12,411.19
in general payments reported to CMS, 2019-2025
35 companies · $2,967 in 2025
The $2,967 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,479 · 2022: $2,220 · 2023: $2,056 · 2024: $3,688 · 2025: $2,967.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,435 · Travel and Lodging: $1,192 · Education: $85.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,434.80 |
| Travel and Lodging | $1,191.80 |
| Education | $85.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,179.17 | 2021-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals LP | $1,858.09 | 2021-2025 | Airsupra, Breztri, Tezspire |
| Inspire Medical Systems, INC. | $1,843.23 | 2022-2025 | Inspire |
| Regeneron Healthcare Solutions, INC. | $1,191.35 | 2021-2025 | Dupixent |
| Insmed, INC. | $585.74 | 2022-2025 | Arikayce, Brinsupri |
| United Therapeutics Corporation | $585.20 | 2021-2025 | Tyvaso, Tyvaso |
| Boehringer Ingelheim Pharmaceuticals, INC. | $563.67 | 2021-2025 | Ofev, Jascayd |
| Genzyme Corporation | $534.42 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $343.32 | 2022-2025 | Zerbaxa, Dificid, Recarbrio |
| Takeda Pharmaceuticals U.S.A., INC. | $295.18 | 2021-2025 | Glassia |
| Mylan Specialty L.P. | $250.56 | 2021-2024 | Yupelri |
| Jazz Pharmaceuticals INC. | $188.75 | 2022-2024 | |
| Lilly USA, LLC | $157.50 | 2025 | Zepbound, Mounjaro |
| Astellas Pharma US INC | $120.89 | 2021-2023 | Cresemba |
| Sanofi-Aventis U.S. LLC | $78.99 | 2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $67.83 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Novartis Pharmaceuticals Corporation | $61.71 | 2022-2025 | |
| Viatris Specialty LLC | $59.12 | 2025 | Yupelri |
| Harmony Biosciences LLC | $52.39 | 2021-2025 | |
| Genentech USA, INC. | $41.93 | 2023-2024 | Xolair |
| Verona Pharma, INC. | $41.03 | 2025 | Ohtuvayre |
| Teva Pharmaceuticals USA, INC. | $34.90 | 2021 | |
| Pulmonx Corporation | $34.05 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Ani Pharmaceuticals, INC. | $31.05 | 2025 | Purified Cortrophin Gel |
| Vifor Pharma, INC. | $29.05 | 2024 | Zemaira |
| Optinose US, INC. | $22.40 | 2024 | |
| 3b Medical, INC. | $22.10 | 2025 | Luna |
| Melinta Therapeutics, LLC | $21.57 | 2023 | Vabomere |
| Amgen INC. | $20.24 | 2022 | |
| Inogen, INC. | $17.69 | 2023 | Inogen At Home Stationary Concentrator |
| Idorsia Pharmaceuticals US INC | $17.56 | 2022 | |
| Horizon Therapeutics Plc | $17.23 | 2023 | Krystexxa |
| Adma Biomanufacturing LLC | $16.47 | 2021 | |
| Resmed Corp | $14.70 | 2024 | |
| Sunovion Pharmaceuticals INC. | $12.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Gann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.